{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T20:45:57Z","timestamp":1773175557155,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.adro.2025.101870","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T15:59:07Z","timestamp":1753372747000},"page":"101870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Extracranial Palliative Radiation Therapy for Renal Cell Carcinoma"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5799-4136","authenticated-orcid":false,"given":"Young Suk","family":"Kwon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maggie","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alana","family":"Christie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelie","family":"Garant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil B.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel X.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihailo","family":"Miljanic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin D.","family":"Courtney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Hammers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waddah","family":"Arafat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Brugarolas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1282-056X","authenticated-orcid":false,"given":"Raquibul","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2025.101870_bib0003","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.clgc.2018.10.002","article-title":"Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: A SEER-based study","volume":"17","author":"Saad","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.adro.2025.101870_bib0004","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: Extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2025.101870_bib0005","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2025.101870_bib0006","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2025.101870_bib0008","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2025.101870_bib0009","article-title":"State of the art: Multidisciplinary management of oligometastatic renal cell carcinoma","volume":"43","author":"Dason","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.adro.2025.101870_bib0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/00365597709179965","article-title":"Preoperative irradiation in the treatment of renal adenocarcinoma","volume":"11","author":"Juusela","year":"1977","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.adro.2025.101870_bib0011","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/1097-0142(197311)32:5<1056::AID-CNCR2820320505>3.0.CO;2-M","article-title":"Proceedings: Carcinoma of the kidney","volume":"32","author":"van der Werf-Messing","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2025.101870_bib0012","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0360-3016(95)02029-2","article-title":"A review of human cell radiosensitivity in vitro","volume":"34","author":"Deschavanne","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2025.101870_bib0013","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S1470-2045(22)00656-8","article-title":"5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: An individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)","volume":"23","author":"Siva","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2025.101870_bib0014","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2023.02.016","article-title":"Phase 2 trial of stereotactic ablative radiotherapy for patients with primary renal cancer","volume":"84","author":"Hannan","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2025.101870_bib0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2018.04.008","article-title":"Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group","volume":"98","author":"Meyer","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.adro.2025.101870_bib0017","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2519::AID-CNCR26>3.0.CO;2-E","article-title":"Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts","volume":"80","author":"Ning","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2025.101870_bib0018","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ijrobp.2007.10.059","article-title":"Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy","volume":"70","author":"Park","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2025.101870_bib0019","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.semradonc.2008.04.004","article-title":"The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction","volume":"18","author":"Brenner","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.adro.2025.101870_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6384253","article-title":"The efficacy of conventionally fractionated radiation in the management of osseous metastases from metastatic renal cell carcinoma","volume":"2018","author":"Ganju","year":"2018","journal-title":"J Oncol"},{"key":"10.1016\/j.adro.2025.101870_bib0021","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/0284186X.2014.939298","article-title":"Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: A systematic review","volume":"54","author":"Kothari","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.adro.2025.101870_bib0022","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1470-2045(21)00196-0","article-title":"Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: An open-label, multicentre, randomised, controlled, phase 2\/3 trial","volume":"22","author":"Sahgal","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2025.101870_bib0023","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jamaoncol.2023.0356","article-title":"Stereotactic radiosurgery vs conventional radiotherapy for localized vertebral metastases of the spine: Phase 3 results of NRG Oncology\/RTOG 0631 randomized clinical trial","volume":"9","author":"Ryu","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2025.101870_bib0024","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3857\/roj.2015.33.4.265","article-title":"Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery","volume":"33","author":"Kim","year":"2015","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.adro.2025.101870_bib0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.cdd.4402269","article-title":"Molecular characteristics of immunogenic cancer cell death","volume":"15","author":"Tesniere","year":"2008","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.adro.2025.101870_bib0026","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2022.10.017","article-title":"Stereotactic body radiation therapy versus conventional radiation therapy in pain relief for bone metastases: A systematic review and meta-analysis","volume":"115","author":"Song","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2025.101870_bib0027","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrurol.2017.87","article-title":"Radiotherapy for renal cell carcinoma: Renaissance of an overlooked approach","volume":"14","author":"Siva","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.adro.2025.101870_bib0028","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nrclinonc.2015.120","article-title":"Opportunities and challenges of radiotherapy for treating cancer","volume":"12","author":"Schaue","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.adro.2025.101870_bib0029","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.1082504","article-title":"Tumor response to radiotherapy regulated by endothelial cell apoptosis","volume":"300","author":"Garcia-Barros","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.adro.2025.101870_bib0030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrc2397","article-title":"Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response","volume":"8","author":"Dewhirst","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.adro.2025.101870_bib0031","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ccr.2005.07.014","article-title":"Engaging the vascular component of the tumor response","volume":"8","author":"Fuks","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.adro.2025.101870_bib0032","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1667\/RR2773.1","article-title":"Radiation-induced vascular damage in tumors: Implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS)","volume":"177","author":"Park","year":"2012","journal-title":"Radiat Res"},{"key":"10.1016\/j.adro.2025.101870_bib0033","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.radonc.2012.10.012","article-title":"Radiation-induced neuropathy in cancer survivors","volume":"105","author":"Delanian","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2025.101870_bib0034","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0360-3016(94)00655-5","article-title":"Radiation response of the central nervous system","volume":"31","author":"Schultheiss","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2025.101870_bib0035","first-page":"199","article-title":"Bone density and fracture risk following SBRT for non-spine bone metastases","volume":"7","author":"Cao","year":"2021","journal-title":"J Radiosurg SBRT"},{"key":"10.1016\/j.adro.2025.101870_bib0036","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/COC.0b013e3180ca7cb1","article-title":"Stereotactic body radiation therapy: A comprehensive review","volume":"30","author":"Chang","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.adro.2025.101870_bib0037","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0360-3016(01)01453-5","article-title":"Organ motion and its management","volume":"50","author":"Langen","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2025.101870_bib0038","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.prro.2021.12.012","article-title":"Cost-effectiveness of treatment strategies for spinal metastases","volume":"12","author":"Kowalchuk","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2025.101870_bib0039","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ijrobp.2014.10.055","article-title":"Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases","volume":"91","author":"Kim","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109425001575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109425001575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:37:58Z","timestamp":1760553478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109425001575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2452109425001575"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2025.101870","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extracranial Palliative Radiation Therapy for Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2025.101870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101870"}}